Hatziandreu E J, Hatzakis A, Hatziyannis S, Kane M A, Weinstein M C
Harvard School of Public Health.
Int J Technol Assess Health Care. 1991;7(3):256-62. doi: 10.1017/s026646230000564x.
We evaluated the cost-effectiveness of (a) a vaccination program for the prevention of hepatitis B; and (b) the two commercially available vaccines (Merck Sharp and Dohme; Pasteur Institute) in Greece, a country of intermediate endemicity. We examined cases of hepatitis-B infection prevented and the expected medical costs among the high-risk groups of medical and nursing students, hospital personnel, and the general population. Employing a vaccination program reduces considerably the risk of infection, especially in the high-risk groups, while it increases the total cost. The vaccines are very comparable in terms of both health and economic outcomes. Sensitivity analysis indicated that vaccine cost, incidence of hepatitis B, and compliance were the key factors for the choice of (a) whether to undertake an extensive program to prevent hepatitis-B infection and its chronic sequelae; and (b) which vaccine to administer.
(a) 一项预防乙型肝炎的疫苗接种计划；以及 (b) 在希腊这个乙型肝炎中度流行的国家，两种市面上可买到的疫苗（默克雪兰诺公司生产的疫苗；巴斯德研究所生产的疫苗）。我们调查了医疗和护理专业学生、医院工作人员以及普通人群等高危群体中预防的乙型肝炎感染病例和预期医疗费用。采用疫苗接种计划可大幅降低感染风险，尤其是在高危群体中，同时会增加总成本。这两种疫苗在健康和经济结果方面非常相似。敏感性分析表明，疫苗成本、乙型肝炎发病率和依从性是决定以下两点的关键因素：(a) 是否开展广泛的计划来预防乙型肝炎感染及其慢性后遗症；以及 (b) 接种哪种疫苗。
